Charge and Spin Currents Generated by Dynamical Spins

We demonstrate theoretically that a charge current and a spin current are generated by spin dynamics in the presence of spin-orbit interaction in the perturbative regime. We consider a general spin-orbit interaction including the spatially inhomogeneous case. Spin current due to spin damping is identified as one origin of generated charge current, but other contributions exist, such as the one due to an induced conservative field and the one arising from the inhomogeneity of spin-orbit interaction.Comment: 14 pages, 4 figure

Conductance fluctuations in the presence of spin scattering

Electron transport through disordered systems that include spin scatterers is studied numerically. We consider three kinds of magnetic impurities: the Ising, the XY and the Heisenberg. By extending the transfer matrix method to include the spin degree of freedom, the two terminal conductance is calculated. The variance of conductance is halved as the number of spin components of the magnetic impurities increases. Application of the Zeeman field in the lead causes a further halving of the variance under certain conditions.Comment: to be published in Phys. Rev.

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer

FLAURA ClinicalTrials.gov number, NCT02296125BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). METHODS: In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-positive (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a standard EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily). The primary end point was investigator-assessed progression-free survival. RESULTS: The median progression-free survival was significantly longer with osimertinib than with standard EGFR-TKIs (18.9 months vs. 10.2 months; hazard ratio for disease progression or death, 0.46; 95% confidence interval [CI], 0.37 to 0.57; P<0.001). The objective response rate was similar in the two groups: 80% with osimertinib and 76% with standard EGFR-TKIs (odds ratio, 1.27; 95% CI, 0.85 to 1.90; P=0.24). The median duration of response was 17.2 months (95% CI, 13.8 to 22.0) with osimertinib versus 8.5 months (95% CI, 7.3 to 9.8) with standard EGFR-TKIs. Data on overall survival were immature at the interim analysis (25% maturity). The survival rate at 18 months was 83% (95% CI, 78 to 87) with osimertinib and 71% (95% CI, 65 to 76) with standard EGFR-TKIs (hazard ratio for death, 0.63; 95% CI, 0.45 to 0.88; P=0.007 [nonsignificant in the interim analysis]). Adverse events of grade 3 or higher were less frequent with osimertinib than with standard EGFR-TKIs (34% vs. 45%). CONCLUSIONS: Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov number, NCT02296125 .).info:eu-repo/semantics/publishedVersio

Effective magnetization damping for a dynamical spin texture in metallic ferromagnet

An additional magnetization damping for an inhomogeneous spin texture in metallic ferromagnets is calculated on the basis of the s–d exchange model. The effect of conduction electrons on the magnetization dynamics is accounted for the case of slowly varying spin texture within adiabatic approximation by using a coordinate transformation to the local quantization axis. The moving magnetic vortex in a circular nanodot made of permalloy is considered as an example. The dependence of the damping on the dot geometrical sizes is obtained. It is found that the additional damping can reach up to 50% of magnitude of the phenomenological Gilbert damping in the Landau–Lifshitz equation of magnetization motion and should be taken into account for any inhomogeneous spin texture dynamics in ferromagnetic metals

Charge and Spin Transport in Magnetic Tunnel Junctions: Microscopic Theory

We study the charge and spin currents passing through a magnetic tunnel junction (MTJ) on the basis of a tight-binding model. The currents are evaluated perturbatively with respect to the tunnel Hamiltonian. The charge current has the form $A[\bm M_1(t)\times\dot{\bm M}_1(t)]\cdot\bm M_2+B\dot{\bm M}_1(t)\cdot\bm M_2$, where $\bm M_1(t)$ and $\bm M_2$ denote the directions of the magnetization in the free layer and fixed layer, respectively. The constant $A$ vanishes when one or both layers are insulators, {while the constant $B$ disappears when both layers are insulators or the same ferromagnets.} The first term in the expression for charge current represents dissipation driven by the effective electric field induced by the dynamic magnetization. In addition, from an investigation of the spin current, we obtain the microscopic expression for the enhanced Gilbert damping constant $\varDelta \alpha$. We show that $\varDelta\alpha$ is proportional to the tunnel conductance and depends on the bias voltage.Comment: 13 pages, 1 figure, accepted for publication in Journal of the Physical Society of Japa

Spin Seebeck insulator

Thermoelectric generation is an essential function of future energy-saving technologies. However, this generation has been an exclusive feature of electric conductors, a situation which inflicts a heavy toll on its application; a conduction electron often becomes a nuisance in thermal design of devices. Here we report electric-voltage generation from heat flowing in an insulator. We reveal that, despite the absence of conduction electrons, a magnetic insulator LaY2Fe5O12 converts a heat flow into spin voltage. Attached Pt films transform this spin voltage into electric voltage by the inverse spin Hall effect. The experimental results require us to introduce thermally activated interface spin exchange between LaY2Fe5O12 and Pt. Our findings extend the range of potential materials for thermoelectric applications and provide a crucial piece of information for understanding the physics of the spin Seebeck effect.Comment: 19 pages, 5 figures (including supplementary information

Perturbation theory of the dynamic inverse spin Hall effect with charge conservation

We present gauge-invariant theory of the dynamic inverse spin Hall effect driven by the spin--orbit interaction in metallic systems. Charge conservation is imposed diagrammatically by including vertex corrections. We show the charge current is induced by an effective electric field that is proportional to the spin current pumped by the magnetization dynamics. The result is consistent with recent experiments.Comment: 16pages, 5figure

Spin Caloritronics

This is a brief overview of the state of the art of spin caloritronics, the science and technology of controlling heat currents by the electron spin degree of freedom (and vice versa).Comment: To be published in "Spin Current", edited by S. Maekawa, E. Saitoh, S. Valenzuela and Y. Kimura, Oxford University Pres

Characteristics and outcomes of patients with advanced non-small-cell lung cancer who declined to participate in randomised clinical chemotherapy trials

There are inadequate data on the outcomes of patients who declined to participate in randomised clinical trials as compared with those of participants. We retrospectively reviewed the patient characteristics and treatment outcomes of both participants and non-participants in the two randomised trials for chemotherapy-naive advanced non-small-cell lung cancer. Trial 1 compared four platinum-based combination regimens. Trial 2 compared two sequences of carboplatin plus paclitaxel and gefitinib therapies. Nineteen of 119 (16%) and 153 (37%) patients declined to participate in Trials 1 and 2, respectively. Among the background patient characteristics, the only variable associated with trial participation or declining was the patients' attending physicians (P<0.001). Important differences were not observed in the clinical outcomes between participants and non-participants, for whom the response rates were 30.6 vs 34.2% and the median survival times were 489 vs 461 days, respectively. The hazard ratio for overall survival, adjusted for other confounding variables, was 0.965 (95% confidence interval: 0.73–1.28). In conclusion, there was no evidence to suggest any difference in the characteristics and clinical outcomes between participants and non-participants. Trial designs and the doctor–patient relationship may have an impact on the patient accrual to randomised trials